MELVILLE, N.Y. — October 6, 2025 — Leads & Copy — BioRestorative Therapies, Inc. (NASDAQ: BRTX) has entered into definitive agreements for the sale of 678,125 shares of its common stock at $1.60 per share in a registered direct offering, alongside a concurrent private placement offering of unregistered warrants to purchase up to 508,594 shares. The gross proceeds are expected to be $1.085 million.
The company intends to use the net proceeds for clinical trials of its lead cell therapy candidate, BRTX-100, pre-clinical research and development of its metabolic ThermoStem® Program, development of its commercial biocosmeceuticals platform, and for general corporate purposes.
The offering is expected to close around October 8, 2025. Alere Financial Partners (a division of Cova Capital Partners, LLC) acted as the exclusive placement agent for the offering.
Lance Alstodt, CEO of BioRestorative, expressed appreciation for the support of new and existing healthcare specialist investors, including their largest institutional shareholder. He believes the investment will position the company to continue executing its strategic goals.
Stephen Kilmer, Investor Relations, Direct: (646) 274-3580, Email: skilmer@biorestorative.com
Source: BioRestorative Therapies, Inc.
